Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.

Altimmune Inc. (NASDAQ:ALT) is poised for a potential breakthrough in the treatment of metabolic-associated steatohepatitis (MASH) and obesity with its lead candidate pemvidutide. With a market ...

Altimmune Inc. (NASDAQ:ALT) is poised for a potential breakthrough in the treatment of metabolic-associated steatohepatitis (MASH) and obesity with its lead candidate pemvidutide. With a market ...

GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and ...

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

GAITHERSBURG, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2025 ...

"Altimmune is reportedly being pursued by three powerhouse suitors seeking to take over the biotech as it seeks to expand its incretin pipeline into alcohol-related disorders, according to a ...

Nasdaq-listed Altimmune Inc. (ALT), on the other hand, sports an eye-watering US$460.7m (£366m) valuation. That is 47x Solvonis’ valuation! The company is developing an AUD treatment in Phase II.

Other groups working on universal flu vaccines include GSK/CureVac, Sanofi, Pfizer, Novavax, FluGen, Vivaldi Biosciences, CodaGenix, BiondVax Pharma, ConserV Bioscience/Imutex, Altimmune ...

At close: May 30 at 4:00:02 p.m. EDT ...